Harmony Biosciences reported preliminary Q2 2026 Wakix revenue of about $261M, up 30% YoY. The company reaffirmed its full-year guidance even as it transitions its CFO. Overall, the strong top-line growth with maintained guidance is a modest positive signal for the stock.
Harmony Biosciences reported preliminary Q2 2026 Wakix revenue of about $261M, up 30% YoY. The company reaffirmed its full-year guidance even as it transitions its CFO. Overall, the strong top-line growth with maintained guidance is a modest positive signal for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
